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Cardiovascular disease is a leading cause of morbidity and mortality in the United States, and its prevention and treatment
remain a priority for the medical community. Ethnic variations account for some diﬀerences in the prevalence of hypertension
and blood pressure (BP) control rates among Hispanics, indicating the need for culturally appropriate management models.
Aggressive treatment strategies are key to achieving optimal BP control in high-risk Hispanic patients. Hypertension in this ethnic
group continues to be a major health concern. Of note, when provided access to comprehensive care, Hispanics demonstrate
similar response rates to treatment as the majority of non-Hispanic whites. This highlights the importance of eﬀective, culturally
responsive hypertension management among high-risk Hispanic patients for achieving observable, positive health outcomes.
1.Introduction
In the United States, cardiovascular disease is a leading
cause of morbidity and mortality; therefore, prevention and
treatment remain a priority for the medical community [1].
Though each ethnic group and segments of the populations
are aﬀected by cardiovascular disease, it has been observed
that socioeconomic and racial factors are strongly correlated
with health. Hypertension awareness often accounts for
minor diﬀerences in blood pressure (BP) control between
Hispanics and non-Hispanics, resulting in the need for cul-
turally appropriate education and management models [2].
2. Acculturation, Language,andHypertension
In the United States, researchers note that factors such as
modernization, education, and structural assimilation were
correlated with favorable BP proﬁles [3]. The prevalence of
hypertensionamongHispanicAmericansappearstoincrease
with the process of acculturation and is inversely correlated
with socioeconomic status [4]. Indeed, acculturation and
language proﬁciency in this ethnic group can be directly
correlated with the incidence of diabetes and associated
morbidities, which have implications for cardiovascular
health [5].
For example, among Mexican Americans, acculturation
and age are strong predictors of hypertension as opposed
to economic status [6]. Based on these ﬁndings, Mexican
American women who are English proﬁcient and had
healthcare coverage were more likely to be screened for
heart disease [7]. This assertion is conﬁrmed by Sundquist
and Winkleby [8], who found that risk of cardiovascular
disease is highest for US-born Spanish-speaking individuals,
intermediate for US-born English-speaking individuals, and
lowest forindividuals ofMexicanorigin. Inspite ofincreased
awareness on the part of both patients and their primary
care providers, Spanish-speaking patients continue to have
higher rates of hypertension, LDL cholesterol, and fasting
blood glucose, when compared to acculturated, or English-
speaking Hispanics [9]. US-born Mexican Americans are2 International Journal of Hypertension
morelikelytoobtainBPscreeningsthantheirMexicancoun-
terparts, highlighting the need for clinicians to carefully note
a patients’ country of origin and other sociodemographic
risk factors, such as lower levels of education [10].
3. HispanicIdentity
Hispanic and Latino individuals are the largest minority
in the US population at over 15 percent. This ethnic
group exhibits a great degree of genetic, physiologic, and
socioeconomic variability.
Due to the complexity of this group, intracultural
variability for the treatment of hypertension in Hispanics
deems greater appreciation. Findings suggest that within
this “single” ethnic group, there are diﬀerences in disease
prevalence and complications and in access to health care.
For example, Getaneh et al. [11] report that Dominican
Americans have a higher incidence of diabetes than Mexican
Americans.
Linetal.[12]reportedthattheincidenceofhypertension
was 66 percent among Puerto Rican men and 73 percent
among Dominican men, compared with 69 percent for non-
Hispanic white men. Also, Hispanic Americans of Caribbean
descent have a hypertension proﬁle similar to that of African
Americans [13].
4. Prevention and Patient Awareness
Awareness is a key in combating hypertension, which is
often described as the “silent disease.” It has been found that
Mexican American hypertensive subjects had signiﬁcantly
poorer BP control than non-Hispanic white hypertensive
subjects. This trend is often attributed to low hypertension
awareness among Hispanics when compared with their
counterparts in other ethnic groups [13].
The most eﬀective way to ensure good health is to
emphasizeahealthy,preventativelifestyle.Preventionbehav-
iors can be taught in childhood and actively practiced
throughadolescenceandintoyoungadulthood.Increasingly,
adolescents are at risk for developing insulin resistance and
worsened cardiovascular disease risk factors [14].
Such risk factors set the stage for obesity, which is placing
young people at risk for diabetes and hypertension [14].
Hispanics have been shown to have a 21 percent greater
prevalence of obesity compared with non-Hispanic whites
[15]. This trend among adolescents suggests prevention and
health literacy beginning should be emphasized at a very
early age by way of school-based and community-based
prevention strategies. Such strategies can directly impact
health outcomes and academic performance [16]. Because
diabetes tends to be diagnosed in Mexican Americans at
younger ages, it is important to screen this population at
earlier timepoints (i.e., adolescence) for hypertension. In
addition, African Americans and Mexican Americans have
the lowest rates of BP control though under treatment
[17]. Speciﬁcally, it has been reported that among patients
with hypertension, medication use was lower in Hispanics
(45%) than in non-Hispanic whites (54%) [18]. These high
rates indicated a need for educational campaigns to raise
awareness.
5. Incidence of Hypertensionin Hispanics
Although historically, Mexican Americans’ prevalence for
heart disease and hypertension has been lower than among
their counterparts in the general population, there has been
an increase since 1993 making it the leading cause of
death among Mexican Americans [10, 19]. This increasing
incidence is partly indicative of a failure to prevent cardio-
vascular disease through management and education [20].
Although BP control and cholesterol levels have im-
proved for adults with cardiovascular disease and diabetes,
in general, diﬀerences in disease control with respect to eth-
nicity and age have not decreased, with hypertension control
remaining higher among non-Hispanic whites [21]. This
demonstrates that, with respect to demographic trends, the
overallincidenceofhypertensionamongMexicanAmericans
continues to be a matter of concern for public health, with
severely adverse outcomes seen in 6 percent of the Mexican
American older population [22].
6. Medications and Treatment
The ﬁndings from ALLHAT (antihypertensive lipid lowering
treatment to prevent heart attack trial) demonstrate that
Hispanic participants had equivalent or superior BP control
comparedwithnon-Hispanicsinaclinicaltrialsettingwhere
patients with hypertension possessed equal access to medical
care. In this trial, medication was also provided at no cost.
Compared with non-Hispanic whites, Hispanic whites had a
20 percent increased likelihood of achieving BP control than
non-Hispanic whites, after adjusting for multiple factors that
predict BP control [23].
Hispanic Americans have higher rates of cardiac morbid-
ity. As a result, researchers have suggested that angiotensin-
converting enzyme inhibitors (ACEIn) and angiotensin II
receptor blockers (ARBs) may be particularly useful in the
Hispanic population owing to the ability of RAAS inhibitors
to protect against end-organ damage caused by hypertension
[24].
The eﬀectiveness of proper medication regimens should
not be underestimated among Hispanic patients. It has been
noted that the use of antihypertensive regimens resulted
in superior BP control and fewer cardiovascular events in
Hispanicwomencomparedwithnon-Hispanicwhitewomen
[25]. Furthermore, it has been found that adherence to
treatment was better among blacks (83.7%) and Hispanics
(83%) than among whites (78.4%) [26].
Several large trials continue to explore this important
line of inquiry. The ongoing telmisartan alone and in
combination with ramipril global endpoint trial (ONTAR-
GET) [27] study suggests that high-risk patients beneﬁt
from combination therapy. In the INVEST (international
verapamil-trandolapril study) trial, no signiﬁcant diﬀer-
ences were noted between verapamil and atenolol-based
strategies for the primary outcome of death and nonfatalInternational Journal of Hypertension 3
myocardial infarction or stroke by ethnicity [28]. The
INVEST researchers discovered that Hispanics, in particular,
had a lower risk of adverse cardiovascular outcomes than
non-Hispanics. A third study, the VALUE (valsartan long-
term use evaluation) trial, found no diﬀerences by ethnicity
between valsartan- and amlodipine-based therapies for the
composite cardiac outcome [29]. Moreover, the INCLUSIVE
study demonstrated that combination therapy led to sub-
stantial decreases in systolic BP among Hispanic patients
[30].
The eﬃcacy of the ACE and ARB combinations has been
demonstrated in many studies. ACE and ARB agents each
havetheirownpharmacologicallyrelevantproﬁles,including
diﬀerent eﬃcacy proﬁles for BP control [31]. There may be
unwanted side eﬀects, such as angioedema, which may be
associated with some ARBs [32].
Some studies have suggested that primary care providers
should aim for more aggressive treatment of their hyper-
tensive patients, regardless of ethnicity [26]. Compliance
withJNCprescribingguidelinesandmoreaggressiveincrease
of medication dosages when indicated can improve rates
of hypertension control and reduce the racial diﬀerences
in hypertension outcomes [26]. Overall, the control rates
of hypertension among Mexican Americans have increased
signiﬁcantly over a period of 5 years and have even been
described as “encouraging” [19].
7. Comorbidities andQualityof Life in
Hispanicswith Hypertension
Comorbidity rates and mortality related to hypertension
may be higher among individuals in the Hispanic commu-
nity. For elderly patients, hypertension and its associated
comorbidities present special challenges. It has been found
that there is a direct correlation between age, the severity
of the hypertension, and cognitive decline among Mexican
Americans aged 65 years or older [33]. Lower extremity
functional limitation (LEFL) is one of the comorbidities
associated with suboptimal prescribing in hypertension [34].
In addition, it has also been noted that psychological eﬀects
caused by hypertension and the need for daily management
can lead to a decreased quality of life [35].
8. Choosing the Right Treatments for
Hypertensionand Comorbidity Management
Targeted eﬀortstoincreasetheuseofACEinhibitorsorARBs
have been shown to improve quality of care for high-risk
patients, regardless of ethnicity.
Several practical clinical management strategies have
been found eﬀective in improving clinical outcomes. For
example, because nonadherence was found to be correlated
with having BP checked in an emergency room, changing
the locus of care for hypertension from emergency rooms to
primary care may improve outcomes [36]. Another strategy,
the dietary approaches to stop hypertension (DASH) combi-
nation diet, may be an eﬀective strategy for preventing and
treating hypertension, particularly in high-risk populations
[37].
9. Special Considerations for HispanicWomen
It has been demonstrated that Hispanic women exhibit
less favorable risk proﬁles for hypertension than non-
Hispanic women [38]. Among younger, perimenopausal
women, African American and Hispanic women exhibited
the lowest rates of control for hypertensive risk factors [39],
a n dh y p e r t e n s i o nc o n t r o lr a t e sc o n t i n u et ob es u b o b t i m a l
for Hispanic women aged 60 years or older [40]. However,
Hispanic women continue to have better treatment and
control rates for hypertension than Hispanic men (Table 1).
10. Promotoras and Community
Health Workers
The Hispanic community has a tradition of relying upon
community health workers, also known as promotoras, to
helpimprovethehealthofindividualsinthecommunity.For
example, The Salud para su Coraz´ on-HRSA initiative was
successful in the development of infrastructure directed at
supported promotoras de salud workforce in the US-Mexico
border region [41]. Reductions in salt and cholesterol intake
were shown to improve through promotora intervention
[41]. A diabetes self-management education program can be
eﬀectively implemented in community settings for glycemic
control [42]. In looking at community-based prevention,
intervention was found to signiﬁcantly increase the number
of women meeting national recommendations for fruit and
vegetable consumption [43].
Community-health workers also play a vital role in
addressing the needs of rural patients. Optimization of
healthcare delivery is needed for Hispanics who live in rural
areas and who tend to be at higher risk for hypertension
and less responsive to primary and specialty care compared
with their urban counterparts [44]. The delivery of rural
healthcare to patients with hypertension requires new strate-
gies such as programs targeting therapeutic inertia, home-
based monitoring of BP, and internet-based communication
programs [45].
11. InnovativeStrategies for
TreatmentandPrevention
Continuing care and lifestyle modiﬁcation are practical,
eﬀective means of controlling hypertension among Hispan-
ics. It has been shown that eﬀective, culturally appropriate
interventions result in increased adherence to lifestyle and
diet modiﬁcation [46].
One approach that has been suggested is a community-
academic partnership, which enabled the successful recruit-
ment, intervention, and assessment of Hispanics at risk for
diabetes [47]. While this approach was adopted with the goal
of reducing the risk of diabetes, its methods can perhaps be
applied to patients with hypertension to achieve BP control.
Another suggested intervention, the use of senior centers4 International Journal of Hypertension
Table 1: Percentage of noninstitutionalized US adults with hypertension∗ and, among those with hypertension, estimated percentage of
persons who are aware of‡, treated for§, and in control of their condition¶, by sex, race/ethnicity, and age group—United States, 1999–2002.
Characteristic∗∗ Hypertension prevalence
% (95% CI‡‡)
Awareness of condition
% (95% CI)
Under current treatment
% (95% CI)
Condition controlled
% (95% CI)
Sex
Men 27.8 (24.9–29.7) 59.4 (55.8–63.1) 45.2 (40.9–49.6) 27.5 (23.7–31.3)
Women 29.0 (27.3–30.8) 69.3 (61.7–77.0) 56.1 (29.2–63.1) 35.5 (28.4–42.7)
Race/Ethnicity
White, non-Hispanic 27.4 (25.3–29.5) 62.9 (57.3–68.5) 48.6 (44.1–53.1) 29.8 (25.7–34.0)
Black, non-Hispanic 40.5 (38.2–42.9) 70.3 (64.9–75.9) 55.4 (51.2–59.6) 29.8 (25.2–34.5)
Mexican American 25.1 (23.1–27.1) 49.8 (40.4–59.2) 34.9 (27.5–42.3) 17.3 (10.7–23.8)
Age group (yrs)
20–39 6.7 (5.3–8.2) 48.7 (38.8–58.7) 28.1 (20.1–36.1) 17.6 (11.6–23.7)
40–59 29.1 (25.9–32.4) 73.5 (69.1–77.90 61.2 (57.1–65.2) 40.5 (36.4–44.5)
≥60 65.2 (62.4–68.0) 72.4 (70.0–74.7) 65.6 (61.9–69.3) 31.4 (28.7–34.2)
Total¶¶ 28.6 (26.8–30.4) 63.4 (59.4–67.4) 45.3 (45.3–52.8) 29.3 (26.0–32.7)
∗Had a blood pressure measurement ≥140mmHg systolic or ≥90mm Hg diastolic or took antihypertensive medication.
‡Told by a health-care professional that blood pressure was high.
§Took antihypertensive medication.
¶Hypertension levels <140mmHg systolic and <90mmHg diastolic.
∗∗All characteristic estimates (excluding age group) are age adjusted [15].
as an intervention point for oﬀering behavioral counseling
and implementing lifestyle changes, has resulted in reduced
systolic BP and increased adherence [48]. Church-based
interventions may be a way to reduce stroke [49]. Culturally
appropriate community-based interventions, such as those
designed to engage individuals in physical activity while
also increasing their awareness of risk factors, can impact
clinical outcomes [50]. Cultural adaptation strategies, such
as Spanish-language intervention models leading to lifestyle-
based management programs, may also be eﬀective [51].
Family-based interventions to raise awareness about
hypertension can be eﬀective, especially if they are admin-
istered through school-based programs that can educate
both parents and children. In fact, it has been demonstrated
that school-based programs are eﬀective and correlated with
reductions in BP among adult family members [52].
Nursingcaremanagementprogramscanalsobeclinically
eﬀective as well as cost eﬀective in a medically indigent,
culturally diverse population and provide an immediate
beneﬁt to a high-risk population [53]. Pharmacists play
an important role in community-based screenings and in
identifying high-risk individuals for cardiac disease [54].
To combat the increasing risk of hypertension and diabetes
in increasingly younger groups, school-based interventions
have been developed and implemented in Southwestern
states [55].
12. Conclusions
Innovative, aggressive, timely treatment, with support in
a community-based context, is needed. Interventions to
reduce disparities in cardiovascular outcomes should con-
sider the need to intensify drug therapy among all high-risk
populations, as the aggressiveness of treatment strategies is
key to achieving optimal BP control in high-risk patients.
Although hypertension continues to be a major health
concern for Hispanics, when these patients are given access
to eﬀective care, they demonstrate the same responsiveness
to treatments as the majority of non-Hispanic white Ameri-
cans.
These ﬁndings highlight the importance of eﬀective,
culturally responsive hypertension management in high-risk
Hispanic patients for achieving observable, positive health
outcomes.
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